Furthermore, IDO1 overexpression has been observed after ICB in NSCLC patients, suggesting a possible role in the process of acquired resistance and has been hypothesized to negatively affect post-treatment prognosis (60). This evidence concerns the gene IDO1 and non-small cell lung carcinoma.